Skip to search formSkip to main contentSkip to account menu

Nesvacumab

Known as: Anti-ANG2 MOAB REGN910, REGN910 
A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ABSTRACT Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related… 
Review
2017
Review
2017
ABSTRACT Introduction: Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular… 
2016
2016
Phase III clinical trials evaluating bevacizumab (an antibody to the angiogenic ligand, VEGF-A) in breast cancer have found… 
2015
2015
Purpose: Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and… 
2014
2014
Angiopoietin-1 (Ang1) and -2 (Ang2) regulate angiogenesis via the endothelial cell-specific receptor tyrosine kinase Tie2… 
Highly Cited
2013
Highly Cited
2013
The angiopoietins Ang1 (ANGPT1) and Ang2 (ANGPT2) are secreted factors that bind to the endothelial cell-specific receptor… 
Review
2013
Review
2013
Anti-VEGF pathway therapies primarily target immature blood vessels in tumors. However, emerging approaches to combine with… 
2013
2013
2517 Background: REGN910 is a selective, fully human Ang2 MAb that potently blocks signaling through the Tie2 receptor regulating… 
2013
2013
TPS2618 Background: REGN910 is a selective, fully human Angiopoietin-2 (ANG-2) MAb, which potently blocks signaling through the… 
2011
2011
TPS159 Background: Angiopoietin-2 (Ang2) is a secreted growth factor that functions as a critical regulator of angiogenesis…